Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5180-5186

  Rubino, Christopher M ^a,b   Forrest, Alan ^a,b   Bhavnani, Sujata M ^a,b   Dukart, Gary ^c   Cooper, Angel ^c   Korth Bradley, Joan ^c   Ambrose, Paul G ^a,b  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TIGECYCLINE;

ADULT; AGED; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG DISTRIBUTION; FEMALE; HOSPITAL INFECTION; HUMAN; LABORATORY TEST; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CROSS INFECTION; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; PNEUMONIA; YOUNG ADULT;

EID: 78649676686     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01414-09     Document Type: Article

References (18)

1. Akaike, H. 1979. A Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 66:237-242.
2. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore. Clin. Infect. Dis. 44:79-86.
3. Bassett, E. J., M. S. Keith, G. J. Armelagos, D. L. Martin, and A. R. Villnueva. 1980. Tetracycline labeled human bone from ancient Sudanese Nubia. Science 209:1532-1534.
4. Bauer, R. J. 2006. S-ADAPT/MCPEM user's guide: software for pharmacokinetic, pharmacodynamic and population data analysis. Biomedical Simulations Resource, Los Angeles, CA. http://bmsr.usc.edu/Software/ADAPT/ SADAPTsoftware.html.
5. Beal, S. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 2:481-504.
6. D'Argenio, D. Z., and A. Schumitzky. 2003. ADAPT II user's guide: pharmacokinetic/ pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
7. D'Argenio, D. Z., and A. Schumitzky. 1979. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput. Programs Biomed. 9:115-134.
8. Duggar, B. M. 1948. Aureomycin: a product of the continuing search for new antibiotics. Ann. N. Y. Acad. Sci. 51:177-181.
9. Freire, A. T., V. Melnyk, M. J. Kim, O. Datsenko, O. Dzyublik, F. Glumcher, Y.-C. Chuang, R. T. Maroko, G. Dukart, C. A. Cooper, J. M. Korth-Bradley, N. Dartois, and H. Gandjini for the 311 Study Group. 2010. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 68:140-151.
10. Meagher, A. K., P. G. Ambrose, T. H. Grasela, and E. J. Ellis-Grosse. 2005. Pharmacokinetic/pharmacodynamic profile for tigecycline - a new glycylcycline antimicrobial agent. Diagn. Microbiol. Infect. Dis. 52:165-171.
11. Meagher, A. K., J. A. Passarell, B. B. Cirincione, S. A. Van Wart, K. Liolios, T. Babinchak, E. J. Ellis-Grosse, and P. G. Ambrose. 2007. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob. Agents Chemother. 51:1939-1945.
12. Muralidharan, G., M. Micalizzi, J. Speth, D. Raible, and S. Troy. 2005. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. 49:220-229.
13. Passarell, J. A., A. K. Meagher, B. B. Cirincione, S. A. Van Wart, T. Babinchak, A. J. Ellis-Grosse, and P. G. Ambrose. 2008. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob. Agents Chemother. 52:204-210.
14. Petersen, P. J., N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. T. Testa. 1999. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:738-744.
15. Rodvold, K. A., M. H. Gotfried, M. Cwik, J. M. Korth-Bradley, G. Dukart, and E. J. Ellis-Grosse. 2006. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J. Antimicrob. Chemother. 58:1221-1229.
16. Schnappinger, D., and W. Hillen. 1996. Tetracyclines: antibiotic action, uptake, and resistance mechanisms. Arch. Microbiol. 165:359-369.
17. Van Wart, S. A., J. S. Owen, E. A. Ludig, A. K. Meagher, J. M. Korth-Bradley, and B. B. Cirincione. 2006. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob. Agents Chemother. 50:3701-3707.
18. Wyeth Pharmaceuticals, Inc. 2009. Tygacil (tigecycline) for injection. Wyeth Pharmaceuticals, Inc., Philadelphia, PA.